There was no harm to the patient due to this event.Siemens team investigated customer return patient sample.Investigation: a plasma sample from the patient sample in question was returned to the (b)(6) site - this sample was not from the initial draw but from the second draw.One (1) replicate of the plasma sample was tested on one (1) stratus cs analyzer (b)(4) using testpak lot 235033002.The initial result obtained was 3.82 ng/ml.A 500 ul of the plasma was then treated with a blocking agent (hbt) from (b)(4) which is composed of specific binders which inactivate heterophilic antibodies.The plasma sample incubated at rt for 1 hour with the blocking reagent and was then tested on the same stratus cs analyzer.The result obtained was 2.46 ng/ml.This result demonstrated a decrease in ctni concentration.When this ctni decrease is considered with what is stated in the product material for the blocking agent, which states if a patient sample is one with an extremely strong heterophilic interference, the blocking agent is unable to block all of the assay interference.Based on these results along with the negative vista result, it appears that there was heterophile antibody interference.Conclusion: along with a negative troponin result on the alternate instrument (siemens vista) at the customer site, internal testing concluded that heterophilic antibody interference caused the false positive troponin result.Treatment with heterophilic antibody blocker reduced the clinical result from 3.82 ng/ml to 2.46 ng/ml.
|